- Home
- SHOO vs NVAX Comparison
SHOO vs NVAX Comparison
Compare SHOO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOO
- NVAX
- Stock Information
- Founded
- SHOO 1990
- NVAX 1987
- Country
- SHOO United States
- NVAX United States
- Employees
- SHOO N/A
- NVAX N/A
- Industry
- SHOO Shoe Manufacturing
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHOO Consumer Discretionary
- NVAX Health Care
- Exchange
- SHOO Nasdaq
- NVAX Nasdaq
- Market Cap
- SHOO 1.4B
- NVAX 1.3B
- IPO Year
- SHOO 1993
- NVAX 1995
- Fundamental
- Price
- SHOO $22.98
- NVAX $5.98
- Analyst Decision
- SHOO Hold
- NVAX Buy
- Analyst Count
- SHOO 7
- NVAX 6
- Target Price
- SHOO $30.50
- NVAX $17.83
- AVG Volume (30 Days)
- SHOO 1.9M
- NVAX 8.1M
- Earning Date
- SHOO 05-07-2025
- NVAX 05-08-2025
- Dividend Yield
- SHOO 3.65%
- NVAX N/A
- EPS Growth
- SHOO N/A
- NVAX N/A
- EPS
- SHOO 2.32
- NVAX 2.97
- Revenue
- SHOO $2,284,080,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- SHOO $19.50
- NVAX N/A
- Revenue Next Year
- SHOO $8.72
- NVAX N/A
- P/E Ratio
- SHOO $9.91
- NVAX $2.01
- Revenue Growth
- SHOO 10.34
- NVAX 25.92
- 52 Week Low
- SHOO $19.05
- NVAX $4.43
- 52 Week High
- SHOO $50.01
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- SHOO 52.36
- NVAX 43.78
- Support Level
- SHOO $19.75
- NVAX $5.82
- Resistance Level
- SHOO $24.24
- NVAX $7.50
- Average True Range (ATR)
- SHOO 1.05
- NVAX 0.56
- MACD
- SHOO 0.64
- NVAX 0.00
- Stochastic Oscillator
- SHOO 71.94
- NVAX 8.71
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.